

Qsymia - ((3.75/23,7.5/46,11.25/69,15/92)mg;Capsule Extended)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | Phentermine Hydrochloride and Topiramate | Innovator | Vivus |
| Dosage | (3.75/23,7.5/46,11.25/69,15/92)mg;Capsule Extended | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | None |
| Final Approvals | Less Than 5 | Generic Launches | Less Than 5 |
| Indication | As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of $\geq 30\text{kg/m}^2$ or $\geq 27\text{kg/m}^2$ in the presence of at least one weight related co-morbidity (eg, hypertension, type 2 diabetes, or dyslipidemia). | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.